Safety and usage pattern of an over-the-counter ambroxol cough syrup: A community pharmacy-based cohort sudy

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 9, 2006, Pages 409-421

  Schulz, M ^a,b   Hammerlein A ^a   Hinkel, U ^c   Weis, G ^c   Gillissen, A ^d  

^a ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d Robert Koch Klinik   (Germany)

Author keywords

Ambroxol; Bronchitis; Cohort study; Over the counter (OTC); Pharmacovigilance; Pharmacy practice; Post marketing surveillance

Indexed keywords

AMBROXOL; NON PRESCRIPTION DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; BRONCHITIS; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMMUNITY CARE; CONSUMER ATTITUDE; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG USE; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL TOXICITY; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE CONGESTION; PATIENT EDUCATION; PHARMACEUTICAL CARE; PHARMACY; QUESTIONNAIRE; SCHOOL CHILD; SELF CONCEPT; SKIN DISEASE; SORE THROAT; SUBCUTANEOUS TISSUE; SYMPTOMATOLOGY; VOMITING; XEROSTOMIA;

EID: 33750713724     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp44409     Document Type: Article

References (22)

1. BfArM. Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln. Empfehlung zur Planung und Durchführung von Anwendungsbeobachtungen. BAnz. 1998; 229: 16884-16885.
2. Bond C, Hannaford P. Issues related to monitoring the safety of over-the-counter (OTC) medicines. Drug Saf. 2003; 26: 1065-1074.
3. Cegla UH. Langzeittherapie über 2 Jahre mit Ambroxol (Mucosolvan) Retardkapseln bei Patienten mit chronischer Bronchitis. Ergebnisse einer Doppelblind-studie an 180 Patienten. Prax Klin Pneumol. 1988; 42: 715-721.
4. Fisher S, Bryant SG. Postmarketing surveillance: accuracy of patient drug attribution judgments. Clin Pharmacol Ther. 1990; 48: 102-107.
5. Germouty J, Jirou-Najou JL. Clinical efficacy of ambroxol in the treatment of bronchial stasis. Clinical trial in 120 patients at two different doses. Respiration. 1987; 51 (Suppl 1): 37-41.
6. van Grootheest K, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf. 2003; 26: 211-217.
7. Guyatt GH, Townsend M, Kazim F, Newhouse MT. A controlled trial of ambroxol in chronic bronchitis. Chest. 1987; 92: 618-620.
8. Hasford J, Fagerstrom KO, Haustein KO. A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation. Eur J Clin Pharmacol. 2003; 59: 443-447.
9. Hasford J, Moore N, Hoye K. Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting. Int J Clin Pharmacol Ther. 2004; 42: 415-422.
10. Jarernsiripornkul N, Krska J, Richards RM, Capps PA. Patient reporting of adverse drug reactions: useful information for pain management? Eur J Pain. 2003; 7: 219-224.
11. 2-receptor antagonists and alginate-containing preparations for dyspepsia. Br J Clin Pharmacol. 2000; 49: 363-368.
12. Layton D, Sinclair HK, Bond CM, Hannaford PC, Shakir SA. Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK. Pharmacoepidemiol Drug Saf. 2002; 11: 503-513.
13. Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther. 2004; 17: 27-34.
14. de Mey C. Sinn und Unsinn von Anwendungsbeobachtungen. Med Klin. 2000; 95: 56-62.
15. Micromedex Healthcare Series. Drugdex® evaluations. Ambroxol. Last accessed: 25 November 2005. Greenwood Village, CO: Thomson Micromedex; 2005.
16. Mitchell AS, Henry DA, Sanson-Fisher R, O'Connell DL. Patients as a direct source of information on adverse drug reactions. BMJ. 1988; 297: 891-893.
17. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst RevCD001287; 2003.
18. Quick JM, Blenkinsopp A. A community pharmacy study to compare the control of hay fever symptoms by astemizole 10 mg and terfenadine 120 mg. Pharm J. 1991; 246: 272-275.
19. Sinclair HK, Bond CM, Hannaford PC. Pharmacovigilance of over-the-counter products based in community pharmacy: a feasible option? Pharmacoepidemiol Drug Saf. 1999; 8: 479-491.
20. Solovitz BL, Fisher S, Bryant SG, Kluge RM. How well can patients discriminate drug-related side effects from extraneous new symptoms? Psychopharmacol Bull. 1987; 23: 189-192.
21. Weingart SN, Gandhi TK, Seger AC, Seger DL, Borus J, Burdick E, Leape LL, Bates DW. Patient-reported medication symptoms in primary care. Arch Intern Med. 2005; 165: 234-240.
22. Weingärtner U. Pharmacy-based observational studies - methodology and evaluation (Die Anwendungsbeobachtung in der Apotheke - Methodik und Evaluierung). Eschborn: Govi Publ Co; 2005.